РОЛЬ НАРУШЕНИЙ УГЛЕВОДНОГО ОБМЕНА В СТАРЕНИИ СЕРДЦА
https://doi.org/10.15829/1728-8800-2017-3-81-86
Аннотация
Собственное старение сердца характеризуется структурно-функциональными изменениями, обусловленными только пожилым возрастом при отсутствии сердечно-сосудистых заболеваний. Нарушения углеводного обмена, в основе которых лежит инсулинорезистентность, часто встречаются у пожилых людей, и усугубляют процессы старения организма, в т.ч. сердца. Структурные изменения сердца при его старении характеризуются развитием концентрического ремоделирования миокарда левого желудочка, а функциональные — нарушением диастолической функции при сохранной систолической. В представленном обзоре описывается влияние старения и нарушений углеводного обмена на структуру и функцию миокарда, и обсуждается все более очевидный факт, что раннее выявление, коррекция нарушений углеводного обмена и инсулинорезистентности могут предотвратить или задержать прогрессирование возраст-ассоциированной сердечной недостаточности.
Ключевые слова
Об авторах
Д. У. АкашеваРоссия
Кандидат медицинских наук, ведущий научный сотрудник отдела изучения процессов старения и профилактики возраст-ассоциированных заболеваний.
Москва, тел.: +7 (903) 526-44-81
И. А. Покшубина
Россия
Врач-кардиолог.
Москва
Е. В. Плохова
Россия
Кандидат медицинских наук, научный сотрудник отдела изучения процессов старения и профилактики возраст-ассоциированных заболеваний.
Москва
О. Н. Ткачева
Россия
Доктор медицинских наук, профессор.
Москва
Список литературы
1. Roger VL, Go AS, Lloyd-Jones DM, et al. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012; 125: 188-97.
2. Ferrari AU, Radaelli A, Centola M. Invited review: aging and the cardiovascular system. J Appl Physiol 2003; 95: 2591-7.
3. Lakatta EG. Heart aging: a fly in the ointment? Circ Res 2001; 88: 984-6.
4. Paternostro G, Vignola C, Bartsch DU, et al. Age-associated cardiac dysfunction in Drosophila melanogaster. Circ Res 2001; 88: 1053.
5. Inuzuka Y, Okuda J, Kawashima T, et al. Suppression of phosphoinositide 3-kinase prevents cardiac aging in mice. Circulation 2009; 120: 1695-703.
6. Lakatta EG. Cardiovascular aging in health. Clin Geriatr Med 2000; 16: 419-44.
7. Levy D. Left ventricular hypertrophy. Epidemiological insights from the Framingham Heart Study. Drugs 1988; 35 (Suppl 5): 1-5.
8. Swinne CJ, Shapiro EP, Jamart J, et al. Age-associated changes in left ventricular outflow tract geometry in normal subjects. Am J Cardiol 1996; 78: 1070-3.
9. Leibowitz D, Gilon D. Echocardiography and the Aging Heart. Current Cardiovascular Imaging Reports 2012; 5(6): 501-6.
10. Kawel N, Turkbey EB, Carr JJ, et al. Normal left ventricular myocardial thickness for middle aged and older subjects with SSFP cardiac MR: The Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Imaging 2012; 5(4): 500-8.
11. Khouri MG, Maurer MS, El-Khoury Rumbarger L. Assessment of age-related changes in left ventricular structure and function by freehand three-dimensional echocardiography. Am J Geriatr Cardiol 2005; 14(3): 118-25.
12. Horn MA, Graham HK, Richards MA, et al. Age-related divergent remodeling of the cardiac extracellular matrix in heart failure: collagen accumulation in the young and loss in the aged. J Mol Cell Cardiol 2012; 53: 82-90.
13. Steiner I, Hájková P. Patterns of isolated atrial amyloid: a study of 100 hearts on autopsy. Cardiovasc Pathol 2006; 15(5): 287-90.
14. Barasch E, Gottdiener JS, Larsen EK, et al. Clinical significance of calcification of thefibrous skeleton of the heart and aortosclerosis in community dwelling elderly. TheCardiovascular Health Study (CHS). Am Heart J 2006; 151: 39-47.
15. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease. Circulation 2003; 107: 346-54.
16. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a “set up” for vascular disease. Circulation 2003; 107: 139-46.
17. Chinnaiyan KM, Alexander D, Maddens M, McCullough PA. Curriculum in cardiology: integrated diagnosis and management of diastolic heart failure. Am Heart J 2007; 153: 189-200.
18. Correia LC, Lakatta EG, O’Connor FC, et al. Attenuated cardiovascular reserve during prolonged submaximal cycle exercise in healthy older subjects. JACC 2002; 40: 1290-7.
19. Dannenberg AL, Levy D, Garrison RJ. Impact of age on echocardiographic left ventricular mass in a healthy population (the Framingham Study). Am J Cardiol 1989; 64: 1066-8.
20. Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nature Reviews Endocrinology 2014; 10: 293-302.
21. Gaggini M, Morelli M, Buzzigoli E, et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013; 5: 1544-60.
22. Ahn J, Lee H, Im SW, et al. Allyl isothiocyanate ameliorates insulin resistance through the regulation of mitochondrial function. The J Nutrit Biochem 2014; 25: 1026-34.
23. Karaca U, Schram MT, Houben AJHM, et al. Microvascular dysfunction as a link between obesity, insulin resistance and hypertension. Diabetes Research and Clinical Practice 2014; 103: 382-7.
24. Li Chen, Rui Chen, HuaWang, Fengxia Liang. Mechanisms Linking Inflammation to Insulin Resistance. International J Endocrinol 2015; Article ID 508409, 9 pages, http://dx.doi.org/10.1155/2015/508409.
25. Kalogeropoulos A, Georgiopoulou V, Harris TB, et al. Glycemic status and incident heart failure in elderly without history of diabetes mellitus: the health, aging, and body composition study. J Card Fail 2009; 15:593-9.
26. Ingelsson E, Sundström J, Arnlöv J, et al. Insulin resistance and risk of congestive heart failure. JAMA 2005; 294: 334-41.
27. Banerjee D, Biggs ML, Mercer L, et al. Insulin Resistance and Risk of Incident Heart Failure. Cardiovascular Health Study. Circ Heart Fail 2013; 6: 364-70.
28. Pagе A, Dumesnil JG, Clavel MA, et al. ASTRONOMER Investigators. Metabolic syndrome is associated with more pronounced impairment of left ventricle geometry and function in patients with calcific aortic stenosis: a substudy of the ASTRONOMER (Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin). JACC 2010; 55: 1867-74.
29. Sundström J, Lind L, Nyström N, et al. Left ventricular concentric remodeling rather than left ventricular hypertrophy is related to the insulin resistance syndrome in elderly men. Circulation 2000; 101: 2595-600.
30. Das SR, Drazner MH, Dries DL, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 2005; 112: 2163-8.
31. Solang L, Malmberg K, Ryden L. Diabetes mellitus and congestive heart failure. Eur Heart J 1999; 20: 789-95.
32. Candido R, Forbes JM, Thomas MC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003; 92: 785-92.
33. Redfield MM, Jacobsen SJ, Burnett Jr JC, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194-202.
34. Delas Fuentes L, Brown AL, Mathews SJ, et al. Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular mass. Eur Heart J 2007; 28: 553-9.
35. Ayalon N, Gopal DM, Mooney DM, et al. Preclinical left ventricular diastolic dysfunction in metabolic syndrome. Am J Cardiol 2014; 114: 838-42.
36. Utsunomiya H, Yamamoto H, Kunita E, et al. Insulin resistance and subclinical abnormalities of global and regional left ventricular function in patients with aortic valve sclerosis. Cardiovasc Diabetol 2014; 13: 86.
37. Abel ED, O’Shea KM, Ramasamy R. Insulin resistance: metabolic mechanisms and consequences in the heart. Arterioscler Thromb Vasc Biol 2012; 32: 2068-76.
38. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007; 115: 3213-23.
39. Anderson EA, Hoffman RP, Balon TW, et al. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991; 87: 2246-52.
40. Park JS, Nam JS, Cho MH, et al. Insulin resistance independently influences arterial stiffness in normoglycemic normotensive postmenopausal women. Menopause 2010; 17: 779-84.
41. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 24: 2035-8.
42. Davis T, Davis WA. Predictors and outcome of heart failure complicating type 2 diabetes: The Fremantle Diabetes Study. American Diabetes Association 2015 Scientific Sessions; June 7, 2015; Boston, MA.
43. Bell DS. Diabetic cardiomyopathy. Diabetes Care 2003; 26: 2949-51.
44. Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function. The strong heart study. Circulation 2000; 101: 2271-6.
45. Rutter MK, Parise H, Benjamin EJ, et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function. Circulation 2003; 107: 448-54.
46. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114: 597-605.
47. Bertoni AG, Tsai A, Kasper EK, Brancati FL. Diabetes and idiopathic cardiomyopathy. A nationwide case-control study. Diabetes Care 2003; 26: 2791-5.
Рецензия
Для цитирования:
Акашева Д.У., Покшубина И.А., Плохова Е.В., Ткачева О.Н. РОЛЬ НАРУШЕНИЙ УГЛЕВОДНОГО ОБМЕНА В СТАРЕНИИ СЕРДЦА. Кардиоваскулярная терапия и профилактика. 2017;16(3):81-86. https://doi.org/10.15829/1728-8800-2017-3-81-86
For citation:
Akasheva D.U., Pokshubina I.A., Plokhova E.A., Tkacheva О.N. CARBOHYDRATE METABOLISM DISORDERS IN THE HEART AGEING. Cardiovascular Therapy and Prevention. 2017;16(3):81-86. (In Russ.) https://doi.org/10.15829/1728-8800-2017-3-81-86